Koolact-L Capsule SR is a sustained-release formulation combining Levosulpiride 75 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders characterized by dyspepsia, gastroesophageal reflux disease (GERD), and functional dysmotility. Levosulpiride, a selective dopamine D2 receptor antagonist, facilitates gastric motility and exhibits prokinetic properties, thereby improving gastric emptying and alleviating symptoms such as nausea, bloating, and abdominal discomfort. Rabeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, promoting mucosal healing and reducing acid-related irritation. The sustained-release mechanism ensures a prolonged therapeutic effect, enhancing patient compliance by reducing dosing frequency. Koolact-L Capsule SR is indicated for patients with acid peptic disorders accompanied by impaired gastric motility, including GERD with delayed gastric emptying and functional dyspepsia. It should be administered under medical supervision, with caution advised in patients with hypersensitivity to the components, severe hepatic or renal impairment, and those on concomitant medications that may interact with dopamine antagonists or proton pump inhibitors. Adverse effects may include mild gastrointestinal disturbances, headache, or extrapyramidal symptoms, warranting prompt medical attention if they occur. This combination therapy offers a comprehensive approach to managing complex gastrointestinal conditions by addressing both acid suppression and motility enhancement.